SITAVIG Drug Patent Profile
✉ Email this page to a colleague
When do Sitavig patents expire, and when can generic versions of Sitavig launch?
Sitavig is a drug marketed by Lnhc and is included in one NDA. There are three patents protecting this drug.
This drug has forty-six patent family members in twenty-nine countries.
The generic ingredient in SITAVIG is acyclovir. There are fifty-six drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the acyclovir profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sitavig
A generic version of SITAVIG was approved as acyclovir by TEVA on April 22nd, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SITAVIG?
- What are the global sales for SITAVIG?
- What is Average Wholesale Price for SITAVIG?
Summary for SITAVIG
| International Patents: | 46 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 184 |
| Clinical Trials: | 1 |
| Patent Applications: | 531 |
| Drug Prices: | Drug price information for SITAVIG |
| What excipients (inactive ingredients) are in SITAVIG? | SITAVIG excipients list |
| DailyMed Link: | SITAVIG at DailyMed |
Recent Clinical Trials for SITAVIG
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Bayer | Phase 3 |
US Patents and Regulatory Information for SITAVIG
SITAVIG is protected by three US patents.
Patents protecting SITAVIG
Mucoadhesive buccal tablets for the treatment of orofacial herpes
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HERPES LABIALIS
Mucosal bioadhesive slow release carrier for delivering active principles
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HERPES LABIALIS
Mucosal bioadhesive slow release carrier for delivering active principles
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HERPES LABIALIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lnhc | SITAVIG | acyclovir | TABLET;BUCCAL | 203791-001 | Apr 12, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Lnhc | SITAVIG | acyclovir | TABLET;BUCCAL | 203791-001 | Apr 12, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Lnhc | SITAVIG | acyclovir | TABLET;BUCCAL | 203791-001 | Apr 12, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SITAVIG
See the table below for patents covering SITAVIG around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 2647123 | VECTEUR MUQUEUX BIOADHESIF A LIBERATION LENTE POUR LA DELIVRANCE DE PRINCIPES ACTIFS (MUCOSAL BIOADHESIVE SLOW RELEASE CARRIER FOR DELIVERING ACTIVE PRINCIPLES) | ⤷ Sign Up |
| Malaysia | 150072 | MUCOSAL BIOADHESIVE SLOW RELEASE CARRIER FOR DELIVERING ACTIVE PRINCIPLES | ⤷ Sign Up |
| Mexico | 2008012186 | PORTADOR BIOADHESIVO MUCOSAL DE LIBERACION RETARDADA PARA EL SUMINISTRO DEL PRINCIPIO ACTIVO. (MUCOSAL BIOADHESIVE SLOW RELEASE CARRIER FOR DELIVERING ACTIVE PRINCIPLES.) | ⤷ Sign Up |
| Israel | 193987 | MUCOSAL BIOADHESIVE SLOW RELEASE CARRIER FOR DELIVERING ACTIVE PRINCIPLES | ⤷ Sign Up |
| Japan | 5242548 | ⤷ Sign Up | |
| Turkey | 201810146 | ⤷ Sign Up | |
| China | 101410092 | Mucosal bioadhesive slow release carrier for delivering active principles | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SITAVIG
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0809498 | SPC/GB10/012 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112 |
| 0809498 | 10C0038 | France | ⤷ Sign Up | PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
